Back Login to subscribe 🔔 Set Alert

LLY Eli Lilly & Co.

15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
LLY Fundamental Data
Loading...
Similar Companies
Loading...
LLY Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
LLY Insider Transactions
Loading insider data…
LLY News
Date Headline Sentiment
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
93.41%
Eli Lilly Says 52-Week Data from TOGETHER-PsO and TOGETHER-PsA Phase 3b trials of the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) Vs. Taltz Alone Shows Improved and Durable Efficacy in Patients With Psoriatic Disease and Obesity
93.81%
Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026
60.77%
Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes
71.98%
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
97.11%
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
88.99%
Eli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.
66.39%
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
96.58%
Ohio Rep. Michael Rulli Sold Up to $100K Worth of Alphabet Stock
57.98%
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
58.66%